IntuBio ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  13.0% 11.9% 3.0% 6.0% 2.1%  
Credit score (0-100)  19 20 56 38 66  
Credit rating  BB BB BBB BBB BBB  
Credit limit (kDKK)  -0.0 0.0 0.0 0.0 0.2  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  718 373 2,283 2,679 4,127  
EBITDA  -717 -808 422 584 2,339  
EBIT  -722 -813 417 334 2,005  
Pre-tax profit (PTP)  -793.8 -912.2 258.0 179.8 1,776.1  
Net earnings  -793.8 -678.2 365.4 369.6 1,396.0  
Pre-tax profit without non-rec. items  -794 -912 258 180 1,776  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  18.4 13.8 9.2 119 88.8  
Shareholders equity total  -744 -422 -56.6 313 1,709  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,167 2,410 2,793 3,833 6,165  

Net Debt  -521 -2,062 -896 -270 -644  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  718 373 2,283 2,679 4,127  
Gross profit growth  0.0% -48.0% 511.8% 17.3% 54.1%  
Employees  2 2 3 3 3  
Employee growth %  0.0% 0.0% 50.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,167 2,410 2,793 3,833 6,165  
Balance sheet change%  0.0% 106.5% 15.9% 37.2% 60.8%  
Added value  -717.1 -808.3 421.8 338.9 2,338.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  14 -9 728 958 -36  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 2.0 3.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -100.6% -217.9% 18.3% 12.5% 48.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -37.8% -34.3% 14.7% 10.4% 40.5%  
ROI %  -52.0% -41.6% 16.1% 23.3% 166.5%  
ROE %  -68.0% -37.9% 14.0% 23.8% 138.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -38.9% -14.9% -2.0% 8.2% 27.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  72.7% 255.1% -212.4% -46.3% -27.5%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.2 7.7 11.0 4.2 4.9  
Current Ratio  2.2 7.7 11.3 4.9 5.5  
Cash and cash equivalent  521.1 2,061.9 895.7 270.2 643.7  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  626.7 2,084.8 1,853.8 1,489.0 3,185.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -359 -404 141 113 780  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -359 -404 141 195 780  
EBIT / employee  -361 -406 139 111 668  
Net earnings / employee  -397 -339 122 123 465